Թիրախային բուժում (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Թիրախային բուժում" in Armenian language version.

refsWebsite

Global rank Armenian rank

21nih.gov

4^th place

3^rd place

11doi.org

2^nd place

4^th place

5worldcat.org

5^th place

10^th place

4cancer.gov

1,684^th place

184^th place

2web.archive.org

1^st place

2clinicaltrials.gov

5,225^th place

3,687^th place

2fda.gov

447^th place

244^th place

1msu.ru

1,129^th place

229^th place

1karger.com

4,489^th place

1,507^th place

1novapublishers.com

low place

1current-oncology.com

low place

1asco.org

low place

1ejcancer.com

low place

1aacrjournals.org

8,869^th place

1,975^th place

1dddmag.com

low place

1europa.eu

68^th place

88^th place

1merck.de

low place

1nytimes.com

7^th place

40^th place

aacrjournals.org

cancerres.aacrjournals.org

«DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells». American Association for Cancer Research. Anne Steino, Guangan He, Jeffrey A. Bacha, Dennis M. Brown and Zahid Siddik.

asco.org

«Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer». 2010. Արխիվացված է օրիգինալից 2012 թ․ մարտի 23-ին. Վերցված է 2020 թ․ փետրվարի 8-ին.

cancer.gov

«Definition of targeted therapy - NCI Dictionary of Cancer Terms».
«Targeted Cancer Therapies». National Cancer Institute.
«National Cancer Institute - Keytruda».
«National Cancer Institute - Pembrolizumab Use in Cancer».

clinicaltrials.gov

«Search of: apatinib - List Results - ClinicalTrials.gov». clinicaltrials.gov.
«VAL-083 Clinical Trials». Clinical Trials . GOV. U.S. National Institutes of Health.

current-oncology.com

Warr MR, Shore GC (2008 թ․ դեկտեմբեր). «Small-molecule Bcl-2 antagonists as targeted therapy in oncology». Curr Oncol. 15 (6): 256–61. PMC 2601021. PMID 19079626.

dddmag.com

«Merck, Endocyte in Development Deal». dddmag.com. 2012 թ․ ապրիլի 25.

doi.org

Heavey, Susan; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ ապրիլ). «Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC». Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. ISSN 1532-1967. PMID 24055012.
Syn, Nicholas Li-Xun; Yong, Wei-Peng; Goh, Boon-Cher; Lee, Soo-Chin (2016 թ․ օգոստոսի 1). «Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review». Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 911–922. doi:10.1080/17425255.2016.1196187. ISSN 1744-7607. PMID 27249175.
Heavey, Susan; Cuffe, Sinead; Finn, Stephen; Young, Vincent; Ryan, Ronan; Nicholson, Siobhan; Leonard, Niamh; McVeigh, Niall; Barr, Martin; O'Byrne, Kenneth; Gately, Kathy (2016 թ․ նոյեմբերի 29). «In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC». Oncotarget. 7 (48): 79526–79543. doi:10.18632/oncotarget.12755. ISSN 1949-2553. PMC 5346733. PMID 27765909.
Heavey, Susan; Dowling, Paul; Moore, Gillian; Barr, Martin P.; Kelly, Niamh; Maher, Stephen G.; Cuffe, Sinead; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2018 թ․ հունվարի 26). «Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines». Scientific Reports. 8 (1): 1652. doi:10.1038/s41598-018-19688-1. ISSN 2045-2322. PMC 5786033. PMID 29374181.
Heavey, Susan; Godwin, Peter; Baird, Anne-Marie; Barr, Martin P.; Umezawa, Kazuo; Cuffe, Sinéad; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ հոկտեմբեր). «Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC». Cancer Biology & Therapy. 15 (10): 1367–1377. doi:10.4161/cbt.29841. ISSN 1555-8576. PMC 4130730. PMID 25025901.
Perantoni AO, Rice JM, Reed CD, Watatani M, Wenk ML (1987 թ․ սեպտեմբեր). «Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea». Proc. Natl. Acad. Sci. U.S.A. 84 (17): 6317–6321. doi:10.1073/pnas.84.17.6317. PMC 299062. PMID 3476947.
Drebin JA, Link VC, Weinberg RA, Greene MI (1986 թ․ դեկտեմբեր). «Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen». Proc. Natl. Acad. Sci. U.S.A. 83 (23): 9129–9133. doi:10.1073/pnas.83.23.9129. PMC 387088. PMID 3466178.
Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (1985 թ․ հուլիս). «Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies». Cell. 41 (3): 697–706. doi:10.1016/S0092-8674(85)80050-7. PMID 2860972.
Zhukov NV, Tjulandin SA (2008 թ․ մայիս). «Targeted therapy in the treatment of solid tumors: practice contradicts theory». Biochemistry Mosc. 73 (5): 605–618. doi:10.1134/S000629790805012X. PMID 18605984.
Markman M (2008). «The promise and perils of 'targeted therapy' of advanced ovarian cancer». Oncology. 74 (1–2): 1–6. doi:10.1159/000138349. PMID 18536523.
Katzel JA, Fanucchi MP, Li Z (2009 թ․ հունվար). «Recent advances of novel targeted therapy in non-small cell lung cancer». J Hematol Oncol. 2 (1): 2. doi:10.1186/1756-8722-2-2. PMC 2637898. PMID 19159467.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Jordan VC (2008 թ․ հունվար). «Tamoxifen: catalyst for the change to targeted therapy». Eur. J. Cancer. 44 (1): 30–38. doi:10.1016/j.ejca.2007.11.002. PMC 2566958. PMID 18068350.
Li J, Zhao X, Chen L, և այլք: (2010). «Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies». BMC Cancer. 10: 529. doi:10.1186/1471-2407-10-529. PMC 2984425. PMID 20923544.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)

ejcancer.com

«Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming chemoresistance in glioblastoma». American Association for Cancer Research. Beibei Zhai, Anna Gobielewska, Anne Steino, Jeffrey A. Bacha, Dennis M. Brown, Simone Niclou and Mads Daugaard.

europa.eu

ema.europa.eu

European medicines Agency (June 2014). “Erbitux® Summary of Product Characteristics (PDF).“ 2015-11-19.

fda.gov

“Therascreen KRAS RGQ PCR Kit – P110030“. Device Approvals and Clearances. U.S. Food and Drug Administration. 2012-07-06.
“Cetuximab (Erbitux). About the Center of Drug Evaluation and Research." U.S. Food and Drug Administration. 2015-11-16.

karger.com

Markman M (2008). «The promise and perils of 'targeted therapy' of advanced ovarian cancer». Oncology. 74 (1–2): 1–6. doi:10.1159/000138349. PMID 18536523.

merck.de

"Merck KGaA: European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer" 2015-11-16

msu.ru

protein.bio.msu.ru

Zhukov NV, Tjulandin SA (2008 թ․ մայիս). «Targeted therapy in the treatment of solid tumors: practice contradicts theory». Biochemistry Mosc. 73 (5): 605–618. doi:10.1134/S000629790805012X. PMID 18605984.

nih.gov

pubmed.ncbi.nlm.nih.gov

Heavey, Susan; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ ապրիլ). «Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC». Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. ISSN 1532-1967. PMID 24055012.
Syn, Nicholas Li-Xun; Yong, Wei-Peng; Goh, Boon-Cher; Lee, Soo-Chin (2016 թ․ օգոստոսի 1). «Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review». Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 911–922. doi:10.1080/17425255.2016.1196187. ISSN 1744-7607. PMID 27249175.
Heavey, Susan; Cuffe, Sinead; Finn, Stephen; Young, Vincent; Ryan, Ronan; Nicholson, Siobhan; Leonard, Niamh; McVeigh, Niall; Barr, Martin; O'Byrne, Kenneth; Gately, Kathy (2016 թ․ նոյեմբերի 29). «In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC». Oncotarget. 7 (48): 79526–79543. doi:10.18632/oncotarget.12755. ISSN 1949-2553. PMC 5346733. PMID 27765909.
Heavey, Susan; Dowling, Paul; Moore, Gillian; Barr, Martin P.; Kelly, Niamh; Maher, Stephen G.; Cuffe, Sinead; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2018 թ․ հունվարի 26). «Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines». Scientific Reports. 8 (1): 1652. doi:10.1038/s41598-018-19688-1. ISSN 2045-2322. PMC 5786033. PMID 29374181.
Heavey, Susan; Godwin, Peter; Baird, Anne-Marie; Barr, Martin P.; Umezawa, Kazuo; Cuffe, Sinéad; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ հոկտեմբեր). «Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC». Cancer Biology & Therapy. 15 (10): 1367–1377. doi:10.4161/cbt.29841. ISSN 1555-8576. PMC 4130730. PMID 25025901.
Perantoni AO, Rice JM, Reed CD, Watatani M, Wenk ML (1987 թ․ սեպտեմբեր). «Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea». Proc. Natl. Acad. Sci. U.S.A. 84 (17): 6317–6321. doi:10.1073/pnas.84.17.6317. PMC 299062. PMID 3476947.
Drebin JA, Link VC, Weinberg RA, Greene MI (1986 թ․ դեկտեմբեր). «Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen». Proc. Natl. Acad. Sci. U.S.A. 83 (23): 9129–9133. doi:10.1073/pnas.83.23.9129. PMC 387088. PMID 3466178.
Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (1985 թ․ հուլիս). «Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies». Cell. 41 (3): 697–706. doi:10.1016/S0092-8674(85)80050-7. PMID 2860972.
Zhukov NV, Tjulandin SA (2008 թ․ մայիս). «Targeted therapy in the treatment of solid tumors: practice contradicts theory». Biochemistry Mosc. 73 (5): 605–618. doi:10.1134/S000629790805012X. PMID 18605984.
Markman M (2008). «The promise and perils of 'targeted therapy' of advanced ovarian cancer». Oncology. 74 (1–2): 1–6. doi:10.1159/000138349. PMID 18536523.
Katzel JA, Fanucchi MP, Li Z (2009 թ․ հունվար). «Recent advances of novel targeted therapy in non-small cell lung cancer». J Hematol Oncol. 2 (1): 2. doi:10.1186/1756-8722-2-2. PMC 2637898. PMID 19159467.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Jordan VC (2008 թ․ հունվար). «Tamoxifen: catalyst for the change to targeted therapy». Eur. J. Cancer. 44 (1): 30–38. doi:10.1016/j.ejca.2007.11.002. PMC 2566958. PMID 18068350.
Warr MR, Shore GC (2008 թ․ դեկտեմբեր). «Small-molecule Bcl-2 antagonists as targeted therapy in oncology». Curr Oncol. 15 (6): 256–61. PMC 2601021. PMID 19079626.
Li J, Zhao X, Chen L, և այլք: (2010). «Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies». BMC Cancer. 10: 529. doi:10.1186/1471-2407-10-529. PMC 2984425. PMID 20923544.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)

ncbi.nlm.nih.gov

Heavey, Susan; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ ապրիլ). «Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC». Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. ISSN 1532-1967. PMID 24055012.
Heavey, Susan; Cuffe, Sinead; Finn, Stephen; Young, Vincent; Ryan, Ronan; Nicholson, Siobhan; Leonard, Niamh; McVeigh, Niall; Barr, Martin; O'Byrne, Kenneth; Gately, Kathy (2016 թ․ նոյեմբերի 29). «In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC». Oncotarget. 7 (48): 79526–79543. doi:10.18632/oncotarget.12755. ISSN 1949-2553. PMC 5346733. PMID 27765909.
Heavey, Susan; Dowling, Paul; Moore, Gillian; Barr, Martin P.; Kelly, Niamh; Maher, Stephen G.; Cuffe, Sinead; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2018 թ․ հունվարի 26). «Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines». Scientific Reports. 8 (1): 1652. doi:10.1038/s41598-018-19688-1. ISSN 2045-2322. PMC 5786033. PMID 29374181.
Heavey, Susan; Godwin, Peter; Baird, Anne-Marie; Barr, Martin P.; Umezawa, Kazuo; Cuffe, Sinéad; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ հոկտեմբեր). «Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC». Cancer Biology & Therapy. 15 (10): 1367–1377. doi:10.4161/cbt.29841. ISSN 1555-8576. PMC 4130730. PMID 25025901.
Perantoni AO, Rice JM, Reed CD, Watatani M, Wenk ML (1987 թ․ սեպտեմբեր). «Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea». Proc. Natl. Acad. Sci. U.S.A. 84 (17): 6317–6321. doi:10.1073/pnas.84.17.6317. PMC 299062. PMID 3476947.
Drebin JA, Link VC, Weinberg RA, Greene MI (1986 թ․ դեկտեմբեր). «Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen». Proc. Natl. Acad. Sci. U.S.A. 83 (23): 9129–9133. doi:10.1073/pnas.83.23.9129. PMC 387088. PMID 3466178.
Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (1985 թ․ հուլիս). «Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies». Cell. 41 (3): 697–706. doi:10.1016/S0092-8674(85)80050-7. PMID 2860972.
Katzel JA, Fanucchi MP, Li Z (2009 թ․ հունվար). «Recent advances of novel targeted therapy in non-small cell lung cancer». J Hematol Oncol. 2 (1): 2. doi:10.1186/1756-8722-2-2. PMC 2637898. PMID 19159467.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Jordan VC (2008 թ․ հունվար). «Tamoxifen: catalyst for the change to targeted therapy». Eur. J. Cancer. 44 (1): 30–38. doi:10.1016/j.ejca.2007.11.002. PMC 2566958. PMID 18068350.
Warr MR, Shore GC (2008 թ․ դեկտեմբեր). «Small-molecule Bcl-2 antagonists as targeted therapy in oncology». Curr Oncol. 15 (6): 256–61. PMC 2601021. PMID 19079626.
Li J, Zhao X, Chen L, և այլք: (2010). «Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies». BMC Cancer. 10: 529. doi:10.1186/1471-2407-10-529. PMC 2984425. PMID 20923544.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)

novapublishers.com

Lacroix, Marc (2014). Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7. Արխիվացված է օրիգինալից 2015 թ․ հունիսի 26-ին. Վերցված է 2020 թ․ փետրվարի 8-ին.

nytimes.com

Pollack, Andrew (2009 թ․ մարտի 31). «F.D.A. Panel Supports Avastin to Treat Brain Tumor». New York Times. Վերցված է 2009 թ․ օգոստոսի 13-ին.

web.archive.org

Lacroix, Marc (2014). Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7. Արխիվացված է օրիգինալից 2015 թ․ հունիսի 26-ին. Վերցված է 2020 թ․ փետրվարի 8-ին.
«Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer». 2010. Արխիվացված է օրիգինալից 2012 թ․ մարտի 23-ին. Վերցված է 2020 թ․ փետրվարի 8-ին.

worldcat.org

Heavey, Susan; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ ապրիլ). «Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC». Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. ISSN 1532-1967. PMID 24055012.
Syn, Nicholas Li-Xun; Yong, Wei-Peng; Goh, Boon-Cher; Lee, Soo-Chin (2016 թ․ օգոստոսի 1). «Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review». Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 911–922. doi:10.1080/17425255.2016.1196187. ISSN 1744-7607. PMID 27249175.
Heavey, Susan; Cuffe, Sinead; Finn, Stephen; Young, Vincent; Ryan, Ronan; Nicholson, Siobhan; Leonard, Niamh; McVeigh, Niall; Barr, Martin; O'Byrne, Kenneth; Gately, Kathy (2016 թ․ նոյեմբերի 29). «In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC». Oncotarget. 7 (48): 79526–79543. doi:10.18632/oncotarget.12755. ISSN 1949-2553. PMC 5346733. PMID 27765909.
Heavey, Susan; Dowling, Paul; Moore, Gillian; Barr, Martin P.; Kelly, Niamh; Maher, Stephen G.; Cuffe, Sinead; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2018 թ․ հունվարի 26). «Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines». Scientific Reports. 8 (1): 1652. doi:10.1038/s41598-018-19688-1. ISSN 2045-2322. PMC 5786033. PMID 29374181.
Heavey, Susan; Godwin, Peter; Baird, Anne-Marie; Barr, Martin P.; Umezawa, Kazuo; Cuffe, Sinéad; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (2014 թ․ հոկտեմբեր). «Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC». Cancer Biology & Therapy. 15 (10): 1367–1377. doi:10.4161/cbt.29841. ISSN 1555-8576. PMC 4130730. PMID 25025901.